• Mashup Score: 0

    About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…

    Tweet Tweets with this article
    • Observation #ENZAMET ✅ Synch Low mHSPC: At 5 yrs on Testosterone suppression (TS) + enzalutamide vs TS + weak blocker (NSAA) ⭕️ 70% on enza vs 33% NSAA ⭕️ 85% PrCa Specific Survival vs 72% NSAA ⭕️ 79% Overall survival vs 67% NSAA @Uromigos @SAiGENCI https://t.co/VKcsC9wE4e https://t.co/lqgrWr7SDw

  • Mashup Score: 14

    About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…

    Tweet Tweets with this article
    • Observation from #ENZAMET ✅ Adding enzalutamide to TS plus docetaxel had the same treatment effect as adding abiraterone (#PEACE1) to darolutamide (#ARASENS) to TS + docetaxel in pts presenting with synchronous mHSPC https://t.co/zj4jsmIhIf https://t.co/KfWLPR8k7O

  • Mashup Score: 2

    Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…

    Tweet Tweets with this article
    • How do the data from the #PEACE1, #ARASENS, and #ENZAMET studies inform clinical practice? @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on UroToday. #WatchNow > https://t.co/UBr8o4aYqO @ASCO https://t.co/d5sRH8p3ue

  • Mashup Score: 0

    Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…

    Tweet Tweets with this article
    • How do the data from the #PEACE1, #ARASENS, and #ENZAMET studies inform clinical practice? @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on UroToday. #WatchNow > https://t.co/UBr8o4aYqO @ASCO https://t.co/tIfsAYrUPZ

  • Mashup Score: 0

    Karim Fizazi and Alicia Morgans discuss the latest ENZAMET updates shared at ASCO 2022. Dr. Fizazi considers the data from the ENZAMET study within the context of findings from the PEACE-1 AND ARASENS trials. In considering the data from these studies, Dr. Fizazi concludes by sharing his treatment recommendations for patients with de novo high volume MET versus de novo low volume MET, as well…

    Tweet Tweets with this article
    • How do the data from the #PEACE1, #ARASENS, and #ENZAMET studies inform clinical practice? @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on UroToday. #WatchNow > https://t.co/UBr8o4bwgm @ASCO https://t.co/Q93UD12hpN

  • Mashup Score: 0

    Ian Davis joins Alicia Morgans in discussing the overall survival (OS) outcomes in ENZAMET (ANZUP 1304), an international, cooperative group randomized phase three cooperative group, open label study, looking at the addition of enzalutamide, for patients with metastatic hormone-sensitive prostate cancer, commencing therapy. At this year’s ASCO meeting, Ian Davis presented the updated OS…

    Tweet Tweets with this article
    • Overall survival outcomes in #ENZAMET (ANZUP 1304), a trial of enzalutamide in metastatic hormone-sensitive #ProstateCancer. @Prof_IanD @easternhealthau joins @CaPsurvivorship @DanaFarber in discussion on UroToday > https://t.co/43pqUKCHRS https://t.co/CVLhRHJ2y5